Novo Nordisk Indiana Plant Faces FDA Rejection, 400 Layoffs Novo Nordisk cut 400 Indiana jobs. FDA rejected multiple client drugs. Manufacturing issues cited by regulators. Supply chain vulnerabilities are exposed. Novo Nordisk announced 400 layoffs at its Indiana manufacturing facility. This follows multiple FDA rejections for drugs produced there for various clients. The rejections stemmed from manufacturing deficiencies, impacting commercialization timelines. While specific drug names are proprietary, at least three client companies faced setbacks. critical quality control failures at a major contract development and manufacturing organization (CDMO). The FDA's actions underscore stringent Current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 211. Rejections typically involve Form 483 observations and Warning Letters, demanding corrective actions. Clients must now resubmit applications, potentially with new manufacturing sites. This procedural delay can extend market entry by months or even years, incurring significant financial penalties and lost revenue. This event impacts the biopharma CDMO landscape. Competitors like Lonza and Catalent may see increased demand as clients seek alternative manufacturing partners. The incident also creates uncertainty for companies relying on large-scale CDMOs. Scholar Rock, a known client, is refiling its drug application, aiming for approval by Q4 2026. This incident stresses the need for robust quality oversight.